Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Talarozole is an inhibitor of cytochrome P450 (CYP) isoform 26 (CYP26; IC50 = 0.004 µM).1 It is selective for CYP26 over CYP2A1, CYP2C11, CYP17, and CYP19 (IC50s = 9.1, 7.2, 2.6, and 1.3 µM, respectively). Talarozole (2.5 mg/kg) increases the levels of all-trans retinoic acid in plasma, skin, liver, fat, kidneys, and spleen in rats. It inhibits estrogen-induced vaginal keratinization in ovariectomized rats (ED50 = 1 mg/kg), an effect that can be reversed by AGN 193109 (Item No. 23975). Talarozole (0.6-2.6 mg/kg) increases pinnal epidermal thickness and tail epidermal orthokeratosis percentage in mice.
WARNING This product is not for human or veterinary use.
1. R115866 inhibits all-